Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

PhaseBio Pharmaceuticals

NASDAQ PHAS
- - -%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 23 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

1.48M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
-33.55M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.59
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
49.18M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-

Upcoming events PhaseBio Pharmaceuticals

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart PhaseBio Pharmaceuticals

Stock analysis PhaseBio Pharmaceuticals

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
0.05 27.22
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
-0.02 3.54
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
0.33 9.69
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
0.34 -0.16
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-23.94 13.82

Price change PhaseBio Pharmaceuticals per year

2.60$ 5.83$
Min Max

Summary analysis PhaseBio Pharmaceuticals

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure PhaseBio Pharmaceuticals

Revenue and net income PhaseBio Pharmaceuticals

All parameters

Stock news PhaseBio Pharmaceuticals

All news
3 November 2021 в 15:45

PhaseBio Pharmaceuticals Trial for Bentracimab Meets Primary Endpoint

3 November 2021 в 15:40

PhaseBio Pharmaceuticals Trial for Bentracimab Meets Primary Endpoint

About company PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.
Address:
1 Great Valley Parkway, Malvern, PA, United States, 19355
Company name: PhaseBio Pharmaceuticals
Issuer ticker: PHAS
ISIN: US7172241090
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2018-10-18
Sector: Healthcare
Industry: Biotechnology
Site: https://phasebio.com

On which stock exchange are PhaseBio Pharmaceuticals (PHAS) stocks traded?

PhaseBio Pharmaceuticals (PHAS) stocks are traded on NASDAQ.

What is the ticker of PhaseBio Pharmaceuticals stocks (PHAS)?

The stock ticker of PhaseBio Pharmaceuticals’s stocks or in other words, the code is PHAS. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does PhaseBio Pharmaceuticals (PHAS) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, PhaseBio Pharmaceuticals (PHAS) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are PhaseBio Pharmaceuticals (PHAS) stocks traded?

PhaseBio Pharmaceuticals (PHAS) stocks are traded on the NASDAQ exchange in dollars.

What is the price of PhaseBio Pharmaceuticals (PHAS) stocks today?

The current price of PhaseBio Pharmaceuticals stocks on 12.05.2024 is dollars. per share.

What is the dynamics of PhaseBio Pharmaceuticals (PHAS) stocks from the beginning of the year?

PhaseBio Pharmaceuticals (PHAS) quotes have increased by 0% from the beginning of the year up to dollars. per 1 stocks.

How much did PhaseBio Pharmaceuticals (PHAS) stocks increase in мае 2024?

This month PhaseBio Pharmaceuticals (PHAS) quotes have increased by 0% to dollars. per share.

How much are PhaseBio Pharmaceuticals (PHAS) stocks worth?

Today, on October, 12.05.2024 PhaseBio Pharmaceuticals’s (PHAS) stocks cost dollars..

What is the market capitalization of PhaseBio Pharmaceuticals (PHAS)?

Capitalization is the market value of PhaseBio Pharmaceuticals (PHAS) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 12.05.2024, the market capitalization of PhaseBio Pharmaceuticals (PHAS) is estimated at about 1480403 dollars.